Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products

Bone Marrow Transplantation

Volumn 44, Issue 4, 2009, Pages 205-211

  Mintz, P D ^a   Wehrli, G ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; CESIUM 137; FLUDARABINE; RIBOFLAVIN;

ANTIMICROBIAL ACTIVITY; BLOOD COMPONENT; BLOOD RADIATION; BLOOD TRANSFUSION REACTION; CLINICAL TRIAL; DISEASE TRANSMISSION; ERADICATION THERAPY; ERYTHROCYTE FRAGILITY; ERYTHROCYTE LIFESPAN; GAMMA IRRADIATION; GRAFT VERSUS HOST REACTION; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; RADIATION EQUIPMENT; REVIEW; RISK REDUCTION; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; ULTRAVIOLET A RADIATION;

BLOOD CELLS; BLOOD TRANSFUSION; CESIUM RADIOISOTOPES; GRAFT VS HOST DISEASE; HUMANS;

EID: 69749123519     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.124     Document Type: Review

References (42)

1. Shimoda T. The case report of post-operative erythroderma. Geka 1955; 17: 487.
2. Hathaway W, Githens J, Blackburn W. Aplastic anemia, histocytosis and erythroderma in immunologically deficient children. N Engl J Med 1965; 273: 953-958.
3. Szaley F, Buki B, Kalouics I, Keleman E. Post-transfusion GVHR in an adult with acute leukemia and aplastic anemia. Orv Hetil 1972; 113: 1275-1280.
4. Rosen R, Heustis D, Corrigan Jr J. Acute leukemia and granulocyte transfusion: Fatal graft versus host reaction following transfusion of cells obtained from normal donors. J Pediatr 1978; 83: 268-270.
5. Lowenthal R, Menon C, Challis D. Graft-versus-host-disease in consecutive patients with acute myeloid leukemia treated with blood cells from normal donors. Aust NZ JMed 1981; 11: 179-183.
6. Postmus P, Mulholland J, Elema J. Graft versus host disease after transfusions of non-irradiated blood cells in patients having received autologous bone marrow: A report of 4 cases following ablative chemotherapy for solid tumors. Eur J Cancer Clin Oncol 1988; 24 889-894.
7. Thaler M, Shamiss A, Orgad S. The role of blood from HLA-homozygous donors in fatal transfusion-associated graftversus-host disease after open-heart surgery. N Engl J Med 1989; 321: 25-28.
8. Whitaker BI, Green J, King MR, Leibeg LL, Schlumpf KS, Schriber GB. The 2007 National Blood Collection and Utilization Survey Report. Department of Health and Human Services: Washington, DC, 2007, p 28.
9. NRC: SECY-08-0184. Strategy for the Security and Use of Cesium-137 Chloride Sources 2008. (http://www.nrc.gov/reading-rm/ doc-collections/commission/secys/2008/secy2008-0184/2008-0184scy.html; accessed on 9 January 2009).
10. America's Blood Centers Newsletter 12 December 2008: P 10.
11. Briz M, Cabrera R, Sanjuan I, Fores R, Diez JL, Herrero M et al. Diagnosis of transfusion-associated graft-versus-host disease by polymerase chain reaction in fludarabine-treated B-chronic lymphocytic leukaemia. Br J Haematol 1995; 91: 409-411.
12. Moroff G, Holme S, AuBuchon JP, Heaton WA, Sweeney JD, Friedman LI. Viability and in vitro properties of AS-1 red cells after gamma irradiation. Transfusion 1999; 39: 128-134.
13. Petrides M, AuBuchon JP. To transfuse or not to transfuse: An assessment of risks and benefits. In: Mintz PD (ed). Transfusion Therapy: Clinical Principles and Practice, 2nd edn. AABB Press: Bethesda, MD, 2005, pp 657-690.
14. Leiby DA, Nguyen ML, Notari EP. Impact of donor deferrals for malaria on blood availability in the United States. Transfusion 2008; 48 2222-2228.
15. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT Trial. Blood 2004; 104: 1534-1541.
16. Lin L, Dikeman R, Molini B, Lukehart SA, Lane R, Dupuis K et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004; 44: 1496-1504.
17. Alter HJ. Pathogen reduction: A precautionary principle paradigm. Transfus Med Rev 2008; 22: 97-102.
18. Reddy HL, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich RP. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev 2008; 22 133-153.
19. Prowse C. Properties of pathogen-inactivated plasma components. Transfus Med Rev 2009; 23: 124-133.
20. Webert KE, Cserti CM, Hannon J, Lin Y, Pavenski K, Pendergrast JM et al. Proceedings of a consensus conference: Pathogen inactivation - making decisions about new technologies. Transfus Med Rev 2008; 22: 1-34.
21. Roback JD, Hossain MS, Lezhava L, Gorechlad JW, Alexander SA, Jaye DL et al. Allogeneic T cells treated with amotosalen prevent lethal cytomegalovirus disease without producing graft-versus-host disease following bone marrow transplantation. J Immunol 2003; 171: 6023-6031.
22. Grass JA, Hei DJ, Metchette K, Cimino GD, Wiesehahn GP, Corash L et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998; 91 2180-2188.
23. Palszynski MM, Moroff G, Luban NL, Taylor BJ, Quinones RR. Effect of gamma irradiation of red blood cell units on T-cell inactivation as assessed by limiting dilution analysis: Implications for preventing transfusion-associated graft-versus-host disease. Blood 1994; 83: 1683-1689.
24. Grass JA, Wafa T, Reames A, Wages D, Corash L, Ferrara JL et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999; 93: 3140-3147.
25. Truitt RL, Johnson BD, Hanke C, Talib S, Hearst JE. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation. J Immunol 1999; 163: 5145-5156.
26. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: The euroSPRITE trial. Blood 2003; 101: 2426-2433.
27. Mintz PD, Bass NM, Petz LD, Steadman R, Streiff M, McCullough J et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006; 107: 3753-3760.
28. Mintz PD, Neff A, MacKenzie M, Goodnough LT, Hillyer C, Kessler C et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006; 46: 1693-1704.
29. de Alarcon P, Benjamin R, Dugdale M, Kessler C, Shopnick R, Smith P et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: Transfusion of patients with congenital coagulation factor deficiencies. Transfusion 2005; 45: 1362-1372.
30. Conlan M, Lin JS, Flament J, Lin L, Corash L. INTERCEPT platelets treated with Helinx technology to inactivate T-cells prevented transfusion-associated graft-versus-host disease (TV-GVHD): Results of 3 clinical trials. VIII European Congress of the International Society of Blood Transfusion 2003. Istanbul, Turkey, pp 22.
31. Cazenave JP, Waller C, Mendel I, Kientz D, Raidot JP, Wiesel ML et al. Impact of photochemical treatment of platelet components (INTERCEPT) on platelet and RBC component use by hematology-oncology patients during routine practice. Transfusion 2008; 48 (S2): 36A (abstract no. S95-030L).
32. Osselaer JC, Doyen C, Graux C, Chatelain C, Sonnet A, Jacquet M et al. Prevention of transfusion-associated graft versus host disease (TA-GVHD) by photochemical treatment of platelet components: Clinical experience in routine use. ASH Annu Meet Abstr 2007; 110: 2885.
33. Osselaer JC, Messe N, Hervig T, Bueno J, Castro E, Espinosa A et al. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008; 48: 1061-1071.
34. Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat M, Barbolla L et al. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008; 94: 315-323.
35. Kumar V, Lockerbie O, Keil SD, Ruane PH, Platz MS, Martin CB et al. Riboflavin and UV-light based pathogen reduction: Extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004; 80: 15-21.
36. Asano H, Lee CY, Fox-Talbot K, Koh CM, Erdinc MM, Marschner S et al. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007; 84: 1174-1182.
37. Fast LD, Dileone G, Li J, Goodrich RP. Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006; 46: 642-648.
38. Fast LD, DiLeone G, Cardarelli G, Li J, Goodrich RP. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-gamma c-/- double knockout mice. Transfusion 2006; 46: 1553-1560.
39. Fast LD, Marschner S, DiLeone G, Doane S, Fitzpatrick C, Goodrich RP. Functional inactivation of human white blood cells in whole blood products using the Mirasol system for whole blood. Transfusion 2008; 48(S2): 169A-170A (abstract no. SP363).
40. Doane S, Reddy H, Fitzpatrick C, Keil S, Goodrich RP. Evaluation of pathogen reduction in whole blood with the Mirasol system for whole blood. Transfusion 2008; 48(S2): 99A (abstract no. SP144).
41. Goodrich RP, Roberts T, Folléa G. Clinical evaluation of Mirasol PRT treated apheresis platelets in thrombocytopenic patients. Transfusion 2008; 48(S2): 20A (abstract no. S49-020G).
42. de Cock P, Vaquero M, Garcia R, Marceno R, Fusco GD, Freitas A et al. The Mirasol evaluation program: Use of Mirasol pathogen reduction technology for platelets in routine clinical practice. Transfusion 2008; 48(S2): 165A-166A (abstract no. SP351).